Mrowietz 2005.

Methods	RCT, placebo‐controlled, double‐blind trial Date of study: not stated Setting: not stated
Participants	Randomised: 175 participants (characteristics not stated) Inclusion criteria Not stated Exclusion criteria Not stated Dropouts and withdrawals Not stated
Interventions	Intervention A. Dimethyl fumarate (n = 105), orally, 240 mg, 3 times/day; 16 weeks Control Intervention B. Placebo (n = 70), orally, 2 capsules, 3 times/day; 16 weeks
Outcomes	Assessments at 16 weeks Primary outcomes of the trial PASI Secondary outcomes of the trial PASI 50 PASI 75 SKINDEX‐29 Side effects
Notes	Funding, quote (abstract) by Biogen Idec, Inc and Fumapharm Abstracts: “Results of a phase III study of a novel oral formulation of dimethyl fumarate in the treatment of moderate to severe plaque psoriasis: efficacy, safety, and quality of life effects” published in 2005 in the JEADV, Suppl. 2 (Poster P/06.97) We asked the study authors to provide the protocol and results by email. Additional data to the publication not provided Finally, as the 'Risk of bias' tool assessment was not possible and there were missing data for the results, Mrowietz 2005 was included in Studies awaiting classification